Mirtazapine
Mirtazapine. α2-adrenergic auto- and heteroreceptor antagonist → increases both noradrenergic and serotonergic firing. Blocks 5-HT2A/2C and 5-HT3… Oral half-life 19 h.
α2-adrenergic auto- and heteroreceptor antagonist → increases both noradrenergic and serotonergic firing. Blocks 5-HT2A/2C and 5-HT3 → released serotonin preferentially activates 5-HT1A. Potent H1 antagonism drives sedation and appetite stimulation. No SERT/NET reuptake inhibition — hence minimal sexual dysfunction or GI side effects of SSRIs.
PK: THE STORED HALF-LIFE FALLS BELOW THE ENTIRE PUBLISHED POPULATION RANGE, and the refutation was already sitting in this record own references: "females and the elderly show higher plasma concentrations than males and young adults" and "The elimination half-life of mirtazapine ranges from 20 to 40 hours". The 19 h came from a healthy-MALE-ONLY cohort — whose abstract never states the dose administered — and is corrected to that study verbatim 18.94 with the subgroup limitation recorded rather than smoothed away. F 0.5 IS RIGHT and its verbatim source was likewise already present: "The absolute bioavailability is approximately 50%, mainly because of gut wall and hepatic first-pass metabolism". V 320 L is refuted — it implies a clearance of 23.3 L/h against a verbatim intravenous 31 L/h, running 2.7 TIMES TOO SLOW — but no abstract publishes a mirtazapine volume in litres, and the one candidate is a set of UNITLESS REGIONAL BRAIN distribution volumes from a PET study, which would be a textbook matrix artefact. Retained, refuted, not replaced. Two references are misfiles, one of them an opioid-and-benzodiazepine overdose study that never mentions this drug.
Pharmacokinetics
- Oral — t½ 18.9 h · F 50% · Vd 320 L
Related compounds
- Opioids — caution
Sources: PMID:10885584, PMID:35224877, PMID:16685260